Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence

Cancer Research

Volumn 69, Issue 3, 2009, Pages 984-991

  Brody, Jonathan R ^a   Hucl, Tomas ^b   Costantino, Christina L ^a   Eshleman, James R ^b   Gallmeier, Eike ^b   Zhu, Heng ^b   Van Der Heijden, Michiel S ^b   Winter, Jordan M ^a   Wikiewicz, Agnieszka K ^a   Yeo, Charles J ^a   Kern, Scott E ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PROTEIN P53; THYMIDINE; THYMIDYLATE SYNTHASE; URIDINE;

ALLELE; ARTICLE; COLON CANCER; CONTROLLED STUDY; DNA MODIFICATION; DNA POLYMORPHISM; DRUG SENSITIVITY; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; TANDEM REPEAT;

ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FLUOROURACIL; GENES, P53; HCT116 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; RNA, MESSENGER; RNA, NEOPLASM; THYMIDINE; THYMIDYLATE SYNTHASE; URIDINE; YEASTS;

EID: 59149097713     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3610     Document Type: Article

References (49)

1. Heidelberger C, Chaudhuri NK, Dannenberg P, et al. Fluorinated pyrimidines: a new class of tumour inhibitory compounds. Nature 1957;179:663-6.
2. Longley DB, Harkin DP, Johnston PG. 5-Flurouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
3. Noordhuis P, Holwerda U, Van der Wilt CL, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 2004;15:1025-32.
4. Santi DV, McHenry CS. 5-Fluoro-2′-deoxyuridylate: covalent complex with thymidylate synthetase. Proc Natl Acad Sci U S A 1972;69:1855-7.
5. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthestase with 5-fluorodeoxyuridylate. Biochemistry 1974;13:471-81.
6. Brody J, Gallmeier E, Yoshimura K, et al. A proposed clinical test for monitoring fluoropyrimidine therapy: detection and stability of thymidylate synthase ternary complexes. Cancer Biol Ther 2006;5:923-7.
7. Showalter SL, Showalter TN, Witkiewicz A, et al. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: is it time to move forward? Cancer Biol Ther 2008;7:986-94.
8. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell cines. Cancer Res 1992;52:4306-12.
9. Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-7.
10. Johnston PG, Benson AB III, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003;21:815-9.
11. Peters GJ, Backus HHJ, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205.
12. Drake JC, Allegra CJ, Johnston PG. Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monocloncal antibody TS 106. Anticancer Drugs 1993;4:431-5.
13. Kawakami K, Omura K, Kanehira E, Watanabe G. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal tumors. Anticancer Res 1999;19:3249-52.
14. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. Cancer Res 2006;66:9369-73.
15. Yawata A, Kim SR, Miyajima A, et al. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Cancer Chemother Pharmacol 2005;56:465-72.
16. Hughey CT, Barbour KW, Berger FG, Berger SH. Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase. Mol Pharmacol 1993;44:316-23.
17. Reilly RT, Forsthoefel AM, Berger FG. Functional effects of amino acid substitutions at residue 33 of human thymidylate synthase. Arch Biochem Biophys 1997;342:338-43.
18. Hoganson DK, Williams AW, Berger SH. Isolation and characterization of a thymidylate synthase-deficient human colon tumor cell line. Biochem Pharmacol 1999;58:1529-37.
19. Bunz F, Hwang PM, Torrance C, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-9.
20. Metzger R, Danenberg K, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998;4:2371-6.
21. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000;18:299-313.
22. Lyss AP, Lilenbaum RC, Harris BE, Diasio RB. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 1993;11:239-40.
23. Kakimoto M, Uetake H, Osanai T, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett 2005;223:103-11.
24. Kornmann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-24.
25. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-7.
26. Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003;8:72-8.
27. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
28. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
29. Cory JG, Breland JC, Carter GL. Effect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells. Cancer Res 1979;39:4905-13.
30. Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci U S A 1997;94:1795-9.
31. Klubes P, Cerna I, Meldon MA. Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol 1982;8:17-21.
32. Hoskins J, Scott Butler J. Evidence for distinct DNA-and RNA-based mechanisms of 5-fluorouracil cytotoxicity in Saccharomyces cerevisiae. Yeast 2007;24:861-70.
33. Gustavsson M, Ronne H. Evidence that tRNA modifying enzymes are important in vivo targets for 5-fluorouracil in yeast. RNA 2008;14:666-74.
34. Vernis L, Piskur J, Diffley JF. Reconstitution of an efficient thymidine salvage pathway in Saccharomyces cerevisiae. Nucleic Acids Res 2003;31:e120.
35. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001;85:827-30.
36. Brody JR, Calhoun ES, Gallmeier E, Creavalle TD, Kern SE. Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media. Biotechniques 2004;37:598, 600, 2.
37. Kitchens ME, Forsthoefel AM, Rafique Z, Spencer HT, Berger FG. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation. J Biol Chem 1999;274:12544-7.
38. Santelli G, Valeriote F. In vivo enhancement of 5-fluorouracil cytotoxicity to AKR leukemia cells by thymidine in mice. J Natl Cancer Inst 1978;61:843-7.
39. Rich MA, Bolaffi JL, Knoll JE, Cheong L, Eidinoff ML. Growth inhibition of a human tumor cell strain by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine; reversal studies. Cancer Res 1958;18:730-5.
40. Maybaum J, Ullman B, Mandel HG, Day JL, Sadee W. Regulation of RNA- and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res 1980;40:4209-15.
41. Drewinko B, Yang LY, Ho DH, Benvenuto J, Loo TL, Freireich EJ. Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines. Cancer 1980;45:1144-58.
42. Gmeiner WH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005;12:191-202.
43. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001;61:4910-5.
44. Arango D, Mariadason JM, Wilson AJ, et al. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003;89:1757-65.
45. Augenlicht LH, Wadler S, Corner G, et al. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 1997;57:1769-75.
46. Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003;63:8791-812.
47. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990;48:381-95.
48. Hucl T, Gallmeier E, Kern SE. Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials. Cell Cycle 2007;6:1336-41.
49. Gallmeier E, Kern SE. Targeting Fanconi anemia/ BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. Clin Cancer Res 2007;13:4-10.